MoonLake climbs after report of Merck buyout talks

MoonLake Immunotherapeutics

03/06/2025 15:26

** Shares of Swiss biotech MoonLake Immunotherapeutics MLTX.O rise 14.8% to $47.25

** Merck MRK.N has held talks to buy MLTX for more than $3 billion, the Financial Times reported on Monday, citing people familiar with the matter

** Merck had submitted a nonbinding offer for MoonLake earlier this year - report

** MRK's initial approach was rejected, but discussions can potentially resume, the report says

** Including session moves, MLTX down 12.6% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))